Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ABBV - AbbVie Inc.


Close
192.87
0   0%

Share volume: 0
Last Updated: Fri 20 Dec 2024 09:01:36 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.46%

PREVIOUS CLOSE
CHG
CHG%

$192.87
-20.90
0.12%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
54%
Profitability 50%
Dept financing 50%
Liquidity 12%
Performance 71%
Company vs Stock growth
vs
Performance
5 Days
0.11%
1 Month
-0.77%
3 Months
-9.42%
6 Months
1.64%
1 Year
13.32%
2 Year
7.54%
Key data
Stock price
$192.87
P/E Ratio 
65.45
DAY RANGE
$171.97 - $192.87
EPS 
$2.99
52 WEEK RANGE
$154.97 - $207.32
52 WEEK CHANGE
$13.32
MARKET CAP 
346.751 B
YIELD 
3.08%
SHARES OUTSTANDING 
1.766 B
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
10/25/2024
BETA 
0.29
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$8,118,127
AVERAGE 30 VOLUME 
$6,899,028
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Recent news